This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Closer Look at Gilead's Slowing Hep C Prescriptions

NEW YORK (TheStreet) -- The number of prescriptions written for Gilead Sciences' (GILD - Get Report) hepatitis C drug Sovaldi are showing signs of slowing growth, even a marginal decline, in the past month. Is this the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play? What does this ultimately mean for Gilead going forward?

Sovaldi has been the best drug launch in history with first quarter sales of $2.3 billion, and is on pace for another record quarter when Gilead reports earnings in July.  Weekly Sovaldi prescription numbers (through the week of June 13) are charted below by ISI Group analyst Mark Schoenebaum. The incredible, vertical red line is Sovaldi, but notice the flattening of the curve in the past month.

A Sovaldi slowdown was expected this summer because doctors and hepatitis C patients are anticipating the U.S. approval of Gilead's next hepatitis C drug, ledipasvir, which will be combined with Sovaldi into a single pill. As we get closer to the FDA approval decision for ledipasvir in October, it makes sense for less acutely sick hepatitis C patients to wait for Gilead's newer and more convenient, single-pill therapy. If this recent flattening of the Sovaldi prescription curve is, indeed, just a warehousing of patients waiting for the Sovaldi-ledipasvir combo pill, then it should have a marginal impact on Gilead's stock price and its long term prospects. Prescription growth will re-accelerate when Gilead's single-pill therapy hits the market.

A second, but less likely, reason for the Sovaldi slowdown is a treatment capacity constraint for hepatitis C patients. In other words, there are only so many patients that U.S. doctors can see and treat in a given quarter, and thus only so many Sovaldi prescriptions that can be written. I'm not sure we've ever seen a drug hit a treatment capacity limit, but it exists, at least theoretically, and would result in slowing prescription growth.

If demand for Sovaldi treatment is overwhelming doctors, then don't expect prescriptions or sales to re-accelerate with the approval/launch of ledipasvir. More likely, Gilead's hepatitis C prescription curve would remain flat (barring a sudden increase in the number of doctors capable of treating hepatitis C patients.) Is this a negative for Gilead? It might be perceived that way, but in reality, treatment constraints would only extend the tail of hepatitis C sales as patients wait longer to be seen by their doctors. A potential risk is competition. Abbvie (ABBV - Get Report), Merck (MRK - Get Report) and Bristol-Myers Squibb (BMY) are racing their own hepatitis C therapies towards approval, so a delay in treating patients might create a larger market opportunity for them.

Insurance companies and some politicians have complained loudly about Sovaldi's $84,000 price tag. Restricting patient access to Sovaldi by insurance companies could explain the slowing prescription growth and would be a significant negative for Gilead. That being said, I find it hard to believe insurers are capable of denying access to Sovaldi over the long term given the drug's outstanding efficacy. At best, insurance companies might slow Gilead's hepatitis C sales and extend the treatment tail.

Of the three explanations for Sovaldi's recent slowdown outlined  above, I believe what we're seeing is most likely the re-warehousing of hepatitis C patients waiting for Gilead's single-pill therapy. If I'm right, the company's hepatitis C prescriptions and sales will resume the vertical growth we saw earlier this year. The alternative explanations can't be ruled out entirely but seem less likely.

Sobek is long Gilead.

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABBV $61.00 0.00%
GILD $88.21 0.00%
MRK $54.84 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs